A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Public ClinicalTrials.gov record NCT07227597. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away
Study identification
- NCT ID
- NCT07227597
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Interventions
- Gocatamig Drug
- I-DXd Drug
- Atezolizumab Drug
- Carboplatin Drug
- Etoposide Drug
- Rescue Medications Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 28, 2026
- Primary completion
- Nov 28, 2030
- Completion
- Dec 29, 2030
- Last update posted
- Aug 20, 2026
2026 – 2030
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Foundation ( Site 0124) | Santa Rosa | California | 95403 | Recruiting |
| University of Colorado, Anschutz Cancer Pavilion ( Site 0125) | Aurora | Colorado | 80045 | Recruiting |
| Orlando Health Cancer Institute ( Site 0108) | Orlando | Florida | 32806 | Recruiting |
| Saint Elizabeth Medical Center Edgewood ( Site 0112) | Edgewood | Kentucky | 41017 | Recruiting |
| Washington University School of Medicine ( Site 0134) | St Louis | Missouri | 63110 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101) | Hackensack | New Jersey | 07601 | Recruiting |
| Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107) | Portland | Oregon | 97213 | Recruiting |
| Avera Cancer Institute- Research ( Site 0104) | Sioux Falls | South Dakota | 57105 | Recruiting |
| The University of Tennessee Medical Center ( Site 0120) | Knoxville | Tennessee | 37920 | Recruiting |
| Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133) | Memphis | Tennessee | 38105 | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville | Tennessee | 37203 | Recruiting |
| Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113) | Houston | Texas | 77030 | Recruiting |
| University of Virginia Health System ( Site 0122) | Charlottesville | Virginia | 22908 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07227597, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07227597 live on ClinicalTrials.gov.